PRRT2 and infection: Importantly, these three PKC agonists exhibit anti-viral activity by downregulating the expression of the HIV-1 receptor CD4 and the coreceptors CXCR4 and CCR5 on the host cell surface, which would lead to the blockade of de novo infection [16,22,25].